1. A first-year medical student is reviewing the mechanism of calcineurin inhibitors (immunosuppressive drugs that work by blocking a key phosphatase enzyme called calcineurin, which controls T-cell activation). She notes that cyclosporine and tacrolimus both inhibit calcineurin but do so by binding to different intracellular proteins called immunophilins. Which intracellular binding protein does cyclosporine bind to form its immunosuppressive complex?
A) FK-binding protein 12 (FKBP-12)
B) Cyclophilin
C) Mechanistic target of rapamycin complex 1 (mTORC1)
D) Nuclear factor of activated T cells (NFAT)
E) Calmodulin
ANSWER: B
Rationale:
Cyclosporine binds to an intracellular protein called cyclophilin (also designated CyP), and the resulting cyclosporine-cyclophilin complex inhibits calcineurin — the phosphatase that normally activates T cells by dephosphorylating NFAT. This is the mechanism that makes cyclosporine immunosuppressive.
Option A: Option A is incorrect: FK-binding protein 12 (FKBP-12) is the immunophilin that binds tacrolimus and sirolimus — not cyclosporine. Remembering which drug binds which immunophilin is clinically important because it explains why these drugs have different binding characteristics and potencies despite sharing the same downstream target.
Option C: Option C is incorrect: mTORC1 is the target inhibited by the sirolimus-FKBP-12 or everolimus-FKBP-12 complex — it is not the binding partner of cyclosporine and is not involved in the calcineurin inhibitor mechanism at all.
Option D: Option D is incorrect: NFAT (nuclear factor of activated T cells) is the downstream substrate of calcineurin — it is dephosphorylated by calcineurin to allow T-cell gene transcription. NFAT is what the drug-immunophilin complex prevents from being activated, not what cyclosporine binds to.
Option E: Option E is incorrect: Calmodulin is the calcium-sensing protein that activates calcineurin after intracellular calcium rises in response to T-cell receptor stimulation. Calmodulin is upstream of calcineurin in the signaling cascade and is not the binding partner of cyclosporine.
2. A kidney transplant recipient is receiving tacrolimus as part of his maintenance immunosuppression regimen. A medical student asks the attending physician how tacrolimus works at the molecular level. The attending explains that tacrolimus enters T cells and binds an intracellular immunophilin, and the resulting drug-protein complex inhibits a key enzyme in the T-cell activation pathway. Which of the following correctly identifies the immunophilin that tacrolimus binds and the enzyme that is subsequently inhibited?
A) Cyclophilin; calcineurin
B) Cyclophilin; mTORC1 (mechanistic target of rapamycin complex 1)
C) FK-binding protein 12 (FKBP-12); mTORC1
D) FK-binding protein 12 (FKBP-12); calcineurin
E) Calmodulin; NFAT (nuclear factor of activated T cells)
ANSWER: D
Rationale:
Tacrolimus binds FK-binding protein 12 (FKBP-12), and the resulting tacrolimus-FKBP-12 complex inhibits calcineurin — the serine-threonine phosphatase that dephosphorylates NFAT and allows it to enter the nucleus to drive IL-2 transcription. Blocking calcineurin prevents T-cell activation and proliferation.
Option A: Option A is incorrect: cyclophilin is the immunophilin that binds cyclosporine, not tacrolimus. Both drugs ultimately inhibit calcineurin, but they bind to different immunophilin proteins — a key distinguishing fact.
Option B: Option B is incorrect: cyclophilin is the binding partner of cyclosporine, and the downstream target inhibited by that complex is calcineurin — not mTORC1. mTOR inhibition is a separate mechanism used by sirolimus and everolimus, which also bind FKBP-12 but form a different complex with a different downstream target.
Option C: Option C is incorrect: the first part is correct — tacrolimus does bind FKBP-12 — but the downstream enzyme inhibited is calcineurin, not mTORC1. Sirolimus and everolimus also bind FKBP-12 but their drug-FKBP-12 complexes inhibit mTORC1 rather than calcineurin; tacrolimus specifically directs its FKBP-12 complex toward calcineurin.
Option E: Option E is incorrect: calmodulin is not an immunophilin and is not the binding target of any calcineurin inhibitor drug. Calmodulin is the calcium-sensing co-activator that enables calcineurin activity — it is upstream of calcineurin in the signaling pathway, not a drug receptor.
3. When a T lymphocyte recognizes a foreign antigen through its T-cell receptor, a signaling cascade is triggered that culminates in interleukin-2 (IL-2) gene transcription — the critical step for T-cell activation and proliferation. A key enzyme called calcineurin (a serine-threonine phosphatase, meaning it removes phosphate groups from proteins) sits in the center of this pathway. What is the direct downstream effect of calcineurin activation in this signaling sequence?
A) Calcineurin dephosphorylates NFAT, allowing it to enter the nucleus and drive IL-2 gene transcription
B) Calcineurin phosphorylates NFAT, causing it to exit the nucleus and halt IL-2 transcription
C) Calcineurin cleaves the T-cell receptor complex, terminating antigen recognition
D) Calcineurin activates mTORC1, which then drives T-cell entry into the cell cycle
E) Calcineurin binds cyclophilin and FKBP-12 simultaneously to form an inhibitory complex
ANSWER: A
Rationale:
Calcineurin is a phosphatase — it removes phosphate groups from its target proteins. Its key substrate in T-cell activation is NFAT (nuclear factor of activated T cells), which exists in the cytoplasm in a phosphorylated (inactive) form. When calcineurin dephosphorylates NFAT, NFAT undergoes a conformational change that exposes a nuclear localization signal, allowing it to translocate into the nucleus where it activates transcription of IL-2 and other T-cell activation genes. Calcineurin inhibitors (cyclosporine and tacrolimus) block this step, preventing IL-2 production and halting T-cell activation.
Option B: Option B is incorrect: calcineurin is a phosphatase, not a kinase — it removes phosphate groups rather than adding them. Phosphorylation of NFAT is what keeps it inactive in the cytoplasm; calcineurin-driven dephosphorylation is what activates it.
Option C: Option C is incorrect: calcineurin does not interact with or cleave the T-cell receptor. It acts entirely intracellularly on downstream second-messenger targets, not on the receptor itself.
Option D: Option D is incorrect: calcineurin and mTORC1 are separate pathways. mTORC1 is activated by cytokine growth signals (particularly IL-2 binding to its receptor) and drives cell cycle progression — this is the pathway targeted by mTOR inhibitors such as sirolimus. mTORC1 is not activated by calcineurin.
Option E: Option E is incorrect: cyclophilin and FKBP-12 are the immunophilins that bind cyclosporine and tacrolimus respectively — they are not substrates or partners of calcineurin in the native signaling pathway. The drug-immunophilin complexes inhibit calcineurin from outside; calcineurin does not normally bind these proteins.
4. A transplant pharmacist is counseling a resident about the relative potency of calcineurin inhibitors. Both cyclosporine and tacrolimus achieve immunosuppression by inhibiting calcineurin, but they differ substantially in the doses required to achieve therapeutic drug concentrations. Which of the following correctly characterizes the comparative potency of these two agents?
A) Cyclosporine is approximately 100-fold more potent than tacrolimus on a weight basis
B) Cyclosporine and tacrolimus have equivalent potency but differ only in their oral bioavailability
C) Tacrolimus is approximately 100-fold more potent than cyclosporine on a weight basis
D) Tacrolimus is more potent but only when used in liver transplantation; potency is equivalent in kidney transplantation
E) Potency differences between the two agents are clinically insignificant because both require therapeutic drug monitoring regardless
ANSWER: C
Rationale:
Tacrolimus is approximately 100-fold more potent than cyclosporine on a weight basis, which means that therapeutic tacrolimus trough concentrations are measured in single-digit ng/mL, whereas cyclosporine concentrations are targeted in the hundreds of ng/mL. This potency difference, combined with tacrolimus demonstrating superior acute rejection rates in head-to-head comparisons, is a primary reason tacrolimus has largely supplanted cyclosporine as the calcineurin inhibitor of choice in most solid organ transplant programs.
Option A: Option A is incorrect: the potency relationship is reversed. Cyclosporine is not more potent than tacrolimus — tacrolimus requires far lower drug concentrations to achieve equivalent immunosuppression.
Option B: Option B is incorrect: the agents are not equipotent. Oral bioavailability differs between the two drugs (both have variable absorption), but the 100-fold potency difference is a genuine pharmacological distinction, not merely a bioavailability effect.
Option D: Option D is incorrect: the potency advantage of tacrolimus over cyclosporine applies across solid organ transplant indications — kidney, liver, heart, and lung — and is not restricted to liver transplantation.
Option E: Option E is incorrect: the potency difference is clinically highly significant. The 100-fold difference in dosing concentrations means that medication errors, drug interactions, and formulation changes have proportionally different absolute effects, and the distinct toxicity profiles of the two agents (tacrolimus being more diabetogenic; cyclosporine causing more hypertension and hyperlipidemia) are directly relevant to individualized drug selection.
5. A medical student is reviewing the principles of therapeutic drug monitoring (TDM — the practice of measuring drug concentrations in blood to ensure a patient is within the therapeutic window) for calcineurin inhibitors. She learns that both cyclosporine and tacrolimus require routine concentration monitoring because of their narrow therapeutic index. Which of the following correctly describes the standard blood sample collection requirement for tacrolimus TDM?
A) Random plasma sample collected at any time of day, processed in a serum separator tube
B) Two-hour post-dose plasma sample (C2), collected in a lithium heparin tube
C) Peak concentration sample collected 1 to 2 hours after the morning dose, processed in plasma
D) Urine sample collected over 24 hours, with tacrolimus concentration normalized to creatinine
E) Pre-dose trough whole blood sample (C0), collected in an EDTA-anticoagulated tube immediately before the morning dose
ANSWER: E
Rationale:
Therapeutic drug monitoring of tacrolimus uses the pre-dose trough concentration (designated C0), collected in an EDTA-anticoagulated whole blood tube immediately before the morning dose. Whole blood — not plasma or serum — is required because tacrolimus distributes approximately 75 to 80% into erythrocytes; separating plasma from cells before assay would yield falsely low concentrations that do not reflect true drug exposure. Target trough values for kidney transplant are 8 to 12 ng/mL in the first three months and 5 to 8 ng/mL during maintenance.
Option A: Option A is incorrect: a random plasma sample would be uninformative because tacrolimus concentrations vary substantially across the dosing interval. Standardizing to the pre-dose trough is essential for reproducibility. Plasma tubes are also incorrect — whole blood is required.
Option B: Option B is incorrect: the 2-hour post-dose sample (C2) is the preferred monitoring parameter for cyclosporine in its microemulsion formulation (Neoral/Gengraf), not for tacrolimus. Tacrolimus monitoring relies on the trough C0 concentration, not the C2.
Option C: Option C is incorrect: peak concentration monitoring is not used for tacrolimus TDM. Unlike some drugs where peak concentrations correlate with efficacy or toxicity, tacrolimus trough concentrations are the validated pharmacokinetic target.
Option D: Option D is incorrect: urine is not used for calcineurin inhibitor monitoring. Both tacrolimus and cyclosporine are eliminated primarily through biliary excretion; less than 1% appears unchanged in urine, making urine sampling clinically uninformative for concentration-guided dosing.
6. A kidney transplant recipient is started on tacrolimus three days after surgery. His serum creatinine rises from 1.4 to 2.1 mg/dL over the following week, and his blood pressure is elevated. His tacrolimus trough level is found to be 14 ng/mL (above the target of 8 to 12 ng/mL). The transplant team reduces the tacrolimus dose, and the creatinine returns toward baseline over the next several days. Which of the following best describes the mechanism responsible for this acute, reversible rise in creatinine caused by calcineurin inhibitors (CNIs)?
A) Direct tubular cell necrosis caused by accumulation of toxic CNI metabolites in the proximal tubule
B) Afferent arteriolar vasoconstriction driven by increased endothelin and thromboxane production and decreased prostaglandin synthesis, reducing glomerular filtration rate
C) Immune-mediated glomerulonephritis triggered by deposition of CNI-antibody complexes in the glomerular basement membrane
D) Irreversible interstitial fibrosis and tubular atrophy caused by CNI-induced transforming growth factor-beta (TGF-β) overproduction
E) Obstructive nephropathy secondary to uric acid crystal deposition in the collecting system
ANSWER: B
Rationale:
The acute, dose-dependent, reversible rise in creatinine caused by calcineurin inhibitors results from afferent arteriolar vasoconstriction in the kidney. CNIs increase production of vasoconstrictors (endothelin and thromboxane) and reduce production of vasodilatory prostaglandins, causing constriction of the afferent arteriole — the vessel that carries blood into the glomerulus. This reduces glomerular capillary pressure and filtration rate, leading to a rise in serum creatinine that is proportional to drug concentration and reverses with dose reduction. This is the acute hemodynamic mechanism of CNI nephrotoxicity.
Option A: Option A is incorrect: direct tubular necrosis from CNI metabolites is not the established mechanism of acute CNI nephrotoxicity. The acute functional injury is hemodynamic (vascular), not cytotoxic.
Option C: Option C is incorrect: immune complex glomerulonephritis is not caused by CNIs. This mechanism is seen in immune-mediated renal diseases such as lupus nephritis or post-infectious glomerulonephritis — it is unrelated to CNI pharmacology.
Option D: Option D is incorrect: interstitial fibrosis, tubular atrophy, and TGF-β-driven structural changes represent chronic structural CNI nephrotoxicity — a distinct and irreversible process that develops with prolonged exposure and does not reverse with dose reduction. This option describes the chronic mechanism, not the acute one seen in the scenario.
Option E: Option E is incorrect: uric acid nephropathy from crystal deposition is not a CNI nephrotoxicity mechanism. CNIs do cause hyperuricemia by reducing renal uric acid excretion, which may contribute to gout, but obstructive uric acid nephropathy is not the mechanism of the acute creatinine rise in this scenario.
7. A transplant physician is counseling a 52-year-old kidney transplant candidate who has borderline fasting glucose and a family history of type 2 diabetes. The physician explains that both calcineurin inhibitors can cause new-onset diabetes after transplantation (NODAT — diabetes developing for the first time in a patient who did not have it before transplant), but that the two agents differ in the magnitude of this risk. Which of the following correctly characterizes the comparative diabetogenic risk of tacrolimus versus cyclosporine?
A) Tacrolimus causes NODAT more frequently than cyclosporine, occurring in approximately 10 to 20% of tacrolimus-treated patients, because tacrolimus more potently impairs pancreatic beta-cell insulin secretion through its FKBP-12 pathway
B) Cyclosporine causes NODAT more frequently than tacrolimus because cyclosporine binds GLUT2 transporters in pancreatic beta cells, directly blocking glucose sensing
C) The two agents have equivalent diabetogenic risk; differences in NODAT rates between the two drugs reflect differences in corticosteroid co-administration rather than the CNI itself
D) Tacrolimus causes NODAT less frequently than cyclosporine because tacrolimus does not penetrate the pancreas due to its high degree of erythrocyte binding
E) Neither agent causes NODAT; new-onset diabetes in transplant recipients is entirely attributable to corticosteroid use in the maintenance regimen
ANSWER: A
Rationale:
Tacrolimus is significantly more diabetogenic than cyclosporine. New-onset diabetes after transplantation (NODAT) occurs in approximately 10 to 20% of patients receiving tacrolimus-based regimens, compared to 5 to 10% with cyclosporine. The mechanism involves tacrolimus more potently impairing insulin secretion from pancreatic beta cells through its FKBP-12 binding pathway. This difference in diabetogenic risk is clinically significant when selecting an immunosuppressive regimen for patients with pre-existing risk factors for diabetes, and monitoring of fasting glucose and HbA1c is standard practice for all transplant recipients on CNIs.
Option B: Option B is incorrect: cyclosporine is not more diabetogenic than tacrolimus, and it does not act by binding GLUT2 transporters in pancreatic beta cells. Cyclosporine does have diabetogenic effects through calcineurin inhibition in beta cells, but these are less pronounced than with tacrolimus.
Option C: Option C is incorrect: the NODAT risk difference between tacrolimus and cyclosporine is a real and established pharmacological distinction, not merely a confounder from differential corticosteroid dosing. Head-to-head trials controlling for corticosteroid exposure consistently demonstrate higher NODAT rates with tacrolimus.
Option D: Option D is incorrect: tacrolimus does distribute extensively into erythrocytes (75 to 80%), but this does not prevent pancreatic exposure — tacrolimus reaches pancreatic tissue and exerts its diabetogenic effects there. Erythrocyte binding is relevant to how blood samples are collected for TDM, not to tissue distribution of the drug.
Option E: Option E is incorrect: both calcineurin inhibitors contribute independently to NODAT risk through pancreatic beta-cell impairment, separate from the contribution of corticosteroids. Corticosteroids are also diabetogenic, but the CNI-specific contribution is well established.
8. A renal transplant team is reviewing cosmetic and dermatological adverse effects of calcineurin inhibitors with a group of students. The attending notes that the two CNIs have distinctly different cosmetic profiles, and that these differences sometimes influence drug selection — particularly in younger patients and women. Which of the following correctly distinguishes the cosmetic adverse effects of cyclosporine from those of tacrolimus?
A) Cyclosporine causes alopecia (hair loss) and gingival hyperplasia; tacrolimus causes hirsutism and oral ulcers
B) Cyclosporine and tacrolimus both cause identical cosmetic effects because both agents inhibit calcineurin in the same tissues
C) Tacrolimus causes hirsutism and gingival hyperplasia; cyclosporine causes alopecia and nail changes
D) Cyclosporine causes hirsutism (excess hair growth) and gingival hyperplasia (overgrowth of the gums); tacrolimus causes alopecia (hair loss) rather than hirsutism
E) Both agents cause hirsutism during the first three months of therapy, with spontaneous resolution regardless of continued drug use
ANSWER: D
Rationale:
Cyclosporine is associated with two prominent cosmetic adverse effects: hirsutism (abnormal excess hair growth, particularly on the face and body) and gingival hyperplasia (overgrowth and swelling of the gum tissue, which can become severe enough to require dental surgery). Tacrolimus, by contrast, causes alopecia (hair loss or thinning) rather than hirsutism — the opposite cosmetic effect on hair. These differences are clinically meaningful because they affect quality of life, patient satisfaction, and adherence, and cyclosporine is sometimes avoided in younger women or patients with pre-existing cosmetic concerns.
Option A: Option A is incorrect: alopecia is the hair-related adverse effect of tacrolimus, not cyclosporine. Cyclosporine causes hirsutism. Both drugs can cause gingival changes, but gingival hyperplasia is a much more prominent and clinically recognized adverse effect of cyclosporine specifically.
Option B: Option B is incorrect: despite sharing the same downstream target (calcineurin), the two drugs have distinct adverse effect profiles, including different cosmetic effects. The pharmacological details of how each drug interacts with tissues beyond lymphocytes differ, producing the characteristic differences in adverse effects.
Option C: Option C is incorrect: hirsutism and gingival hyperplasia are adverse effects of cyclosporine, not tacrolimus. The options in this choice reverse the drug-effect pairing.
Option E: Option E is incorrect: the hirsutism associated with cyclosporine typically persists throughout the duration of treatment. It does not spontaneously resolve while the drug is continued. Gingival hyperplasia similarly tends to persist or progress with continued cyclosporine use.
9. A kidney transplant recipient on a stable tacrolimus dose is diagnosed with an invasive fungal infection and started on voriconazole (a triazole antifungal drug). Three days later, his tacrolimus trough concentration has risen from 7 ng/mL to 24 ng/mL, and he develops tremor and a rising creatinine. Which pharmacokinetic mechanism best explains this dangerous rise in tacrolimus levels?
A) Voriconazole competes with tacrolimus for renal tubular secretion, reducing tacrolimus elimination and causing accumulation
B) Voriconazole displaces tacrolimus from plasma protein binding sites, increasing the free (active) fraction of tacrolimus in the blood
C) Voriconazole is a potent inhibitor of the liver enzyme CYP3A4 (cytochrome P450 3A4), which is responsible for metabolizing tacrolimus; blocking this enzyme reduces tacrolimus breakdown and causes drug accumulation
D) Voriconazole directly inhibits calcineurin, additively enhancing the immunosuppressive effect of tacrolimus and producing toxicity through excessive immunosuppression
E) Voriconazole alkalinizes urine, reducing tacrolimus renal clearance by trapping the drug in ionized form in the tubular lumen
ANSWER: C
Rationale:
Tacrolimus is primarily metabolized by cytochrome P450 3A4 (CYP3A4) in the liver and intestinal wall, and is also a substrate of P-glycoprotein (P-gp) efflux transporter. Voriconazole, like other azole antifungal agents (fluconazole, itraconazole, posaconazole), is a potent inhibitor of CYP3A4. When CYP3A4 is inhibited, tacrolimus is metabolized far more slowly, causing it to accumulate in the blood to potentially toxic concentrations — sometimes several-fold above the therapeutic target. This interaction is predictable and must be anticipated whenever an azole antifungal is introduced in a transplant patient on a CNI. Standard management is a pre-emptive tacrolimus dose reduction (typically 30 to 60%) with immediate trough monitoring.
Option A: Option A is incorrect: tacrolimus is not eliminated by renal tubular secretion — it is metabolized by CYP3A4 and eliminated primarily through biliary excretion. Less than 1% of tacrolimus appears unchanged in urine. Renal competition is not the mechanism.
Option B: Option B is incorrect: protein displacement interactions are rarely clinically significant by themselves because the displaced drug is rapidly redistributed and eliminated. More importantly, this is not the mechanism of azole-CNI interaction.
Option D: Option D is incorrect: voriconazole does not inhibit calcineurin and has no direct pharmacodynamic interaction with tacrolimus at its molecular target. The interaction is pharmacokinetic (drug metabolism), not pharmacodynamic (shared target).
Option E: Option E is incorrect: urinary pH manipulation does not meaningfully affect tacrolimus clearance. Tacrolimus is a lipophilic drug eliminated primarily through biliary excretion, not by renal tubular mechanisms that would be sensitive to urine pH.
10. A kidney transplant recipient on a stable tacrolimus regimen is diagnosed with active pulmonary tuberculosis (TB) and requires rifampin-based combination therapy. The transplant pharmacist warns the team that this drug combination requires urgent tacrolimus dose adjustment. Which of the following best describes the mechanism and expected direction of the drug interaction between rifampin and tacrolimus?
A) Rifampin inhibits CYP3A4 in the liver, dramatically reducing tacrolimus metabolism and causing toxic drug accumulation
B) Rifampin chelates tacrolimus in the gastrointestinal tract, reducing its absorption and requiring administration at separate times of day
C) Rifampin competes with tacrolimus at the calcineurin binding site, reducing its immunosuppressive efficacy without affecting drug levels
D) Rifampin causes renal tubular secretion of tacrolimus by activating P-glycoprotein in proximal tubular cells, increasing its urinary elimination
E) Rifampin is a potent inducer of CYP3A4 and P-glycoprotein, dramatically increasing tacrolimus metabolism and transport, reducing tacrolimus AUC (total drug exposure) by 70 to 90% and risking acute rejection
ANSWER: E
Rationale:
Rifampin (rifampicin) is one of the most potent inducers of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) efflux transporter. Because tacrolimus is a substrate of both CYP3A4 and P-gp, coadministration with rifampin dramatically accelerates tacrolimus metabolism and increases its intestinal efflux, reducing tacrolimus area under the curve (AUC — the measure of total drug exposure over time) by approximately 70 to 90%. This reduction in drug exposure is severe enough to precipitate acute allograft rejection within days if the tacrolimus dose is not increased — sometimes 3 to 5-fold or more. Twice-weekly trough monitoring is required at both initiation and discontinuation of rifampin because the induction effect develops over days and reverses over days to weeks. Wherever possible, rifabutin (a weaker CYP3A4 inducer) is substituted for rifampin in transplant patients with TB.
Option A: Option A is incorrect: rifampin is an enzyme inducer, not an inhibitor. Inhibitors raise drug levels; inducers lower them. Rifampin lowers tacrolimus concentrations, not raises them — the opposite of what this option states.
Option B: Option B is incorrect: rifampin does not chelate tacrolimus in the gastrointestinal tract. Chelation interactions are characteristic of drugs like antacids, calcium, or iron with fluoroquinolones or tetracyclines — not the mechanism of the rifampin-tacrolimus interaction.
Option C: Option C is incorrect: rifampin has no pharmacodynamic interaction at the calcineurin binding site. The interaction is entirely pharmacokinetic — rifampin affects how quickly tacrolimus is metabolized and eliminated, not how the drug interacts with its molecular target.
Option D: Option D is incorrect: while P-gp is activated by rifampin in the intestinal wall (reducing absorption) and potentially in the liver (increasing biliary efflux), the clinically dominant mechanism is CYP3A4 induction reducing hepatic metabolism. Proximal tubular P-gp induction is not the primary driver of the interaction.
11. A pharmacy student notes that sirolimus (rapamycin) and tacrolimus both bind to the same intracellular immunophilin protein (FKBP-12, or FK-binding protein 12), yet they have completely different mechanisms of immunosuppressive action. Which of the following correctly identifies the downstream target inhibited by the sirolimus-FKBP-12 complex that distinguishes it from the tacrolimus-FKBP-12 complex?
A) The sirolimus-FKBP-12 complex inhibits calcineurin — the same enzyme inhibited by tacrolimus — but at a different binding site, producing additive immunosuppression
B) The sirolimus-FKBP-12 complex inhibits mTORC1 (mechanistic target of rapamycin complex 1), a serine-threonine kinase that drives cell cycle progression from G1 to S phase; this is distinct from calcineurin, which is the target of the tacrolimus-FKBP-12 complex
C) The sirolimus-FKBP-12 complex inhibits NFAT directly in the nucleus, preventing IL-2 gene transcription at a step downstream of calcineurin
D) The sirolimus-FKBP-12 complex inhibits inosine monophosphate dehydrogenase (IMPDH), blocking purine synthesis in lymphocytes — the same mechanism as mycophenolate mofetil
E) The sirolimus-FKBP-12 complex inhibits P-glycoprotein, trapping lymphocytes in lymph nodes and preventing their migration to the allograft
ANSWER: B
Rationale:
Sirolimus and everolimus form drug-FKBP-12 complexes that inhibit mTORC1 (mechanistic target of rapamycin complex 1), a serine-threonine kinase that serves as the central integrator of nutrient and growth factor signals in cells. mTORC1 drives cell cycle progression from the G1 (gap 1) phase to the S (synthesis) phase by phosphorylating downstream effectors (S6 kinase 1 and 4E-BP1) required for protein synthesis and cell division. In T cells, this pathway amplifies the proliferative response to IL-2. This is mechanistically distinct from the tacrolimus-FKBP-12 complex, which inhibits calcineurin — a phosphatase acting upstream of IL-2 production. The complementary mechanisms of CNIs and mTOR inhibitors are the pharmacological rationale for their use in combination.
Option A: Option A is incorrect: sirolimus does not inhibit calcineurin. Despite binding the same immunophilin (FKBP-12), the drug-FKBP-12 complex is directed toward an entirely different downstream target (mTORC1 versus calcineurin). These drugs are mechanistically complementary, not redundant at the same enzyme.
Option C: Option C is incorrect: mTOR inhibitors do not directly inhibit NFAT. NFAT is downstream of calcineurin — its dephosphorylation and nuclear translocation are events that mTOR inhibitors do not block. mTOR inhibitors act on the proliferative response to IL-2 rather than on IL-2 transcription.
Option D: Option D is incorrect: IMPDH (inosine monophosphate dehydrogenase) inhibition is the mechanism of mycophenolate mofetil (MMF), not sirolimus. These are separate drug classes with separate targets.
Option E: Option E is incorrect: sirolimus does not inhibit P-glycoprotein. In fact, sirolimus is itself a substrate of P-glycoprotein, which affects its absorption and elimination. P-gp inhibition is not the mechanism of action of any approved immunosuppressant.
12. When IL-2 (interleukin-2) binds to its receptor on the surface of a T lymphocyte, it triggers a signaling cascade that drives the T cell from a resting state into active division. The mechanistic target of rapamycin complex 1 (mTORC1 — a central regulatory kinase that integrates signals controlling cell growth and proliferation) sits within this cascade. At which point in the T-cell proliferation cycle do mTOR inhibitors such as sirolimus block T-cell division?
A) mTOR inhibitors block the transition from the G1 phase (gap 1 — a preparatory growth phase) to the S phase (DNA synthesis phase) of the cell cycle, preventing T cells from entering DNA replication in response to IL-2 signaling
B) mTOR inhibitors block the transition from the S phase to the G2 phase, preventing T cells from completing DNA replication once synthesis has already begun
C) mTOR inhibitors arrest T cells in mitosis (M phase) by stabilizing the mitotic spindle and preventing chromosome separation
D) mTOR inhibitors prevent T cells from exiting G0 (quiescent resting state) in response to any stimulus, including T-cell receptor activation
E) mTOR inhibitors block T cells in the G2 phase by inhibiting the cyclin-dependent kinases (CDKs) required for entry into mitosis
ANSWER: A
Rationale:
mTOR inhibitors (sirolimus and everolimus) block T-cell progression from the G1 phase (gap 1, a preparatory phase after cell growth signals) to the S phase (DNA synthesis phase). After T-cell receptor activation drives IL-2 production (a step blocked by calcineurin inhibitors), IL-2 binds to its receptor and activates mTORC1 via the PI3K-Akt pathway. mTORC1 promotes cell cycle progression into S phase by phosphorylating S6 kinase 1 (S6K1) and 4E-BP1, driving ribosome biogenesis and protein synthesis required for the G1-to-S transition. When mTORC1 is inhibited by sirolimus or everolimus, T cells receive the IL-2 signal but cannot enter DNA replication — halting clonal expansion. This is why mTOR inhibitors are described as acting downstream of calcineurin inhibitors.
Option B: Option B is incorrect: mTOR inhibitors block the G1-to-S transition, before DNA replication begins — not the S-to-G2 transition, which occurs during or after DNA synthesis.
Option C: Option C is incorrect: mitotic spindle stabilization is the mechanism of taxane chemotherapy agents such as paclitaxel, which arrest cells in mitosis. mTOR inhibitors act at the G1/S checkpoint, long before mitosis begins.
Option D: Option D is incorrect: mTOR inhibitors do not prevent T cells from exiting G0 in response to T-cell receptor activation. The initial activation steps (antigen recognition, early signaling, and IL-2 production) proceed normally — the block is in the proliferative response to IL-2, not in the initial activation step. Calcineurin inhibitors are the drugs that block upstream activation.
Option E: Option E is incorrect: cyclin-dependent kinase (CDK) inhibition at the G2/M checkpoint is not the mechanism of mTOR inhibitors. CDK inhibitors are a separate class of cell cycle-targeted drugs used primarily in oncology, not in transplant immunosuppression.
13. A kidney transplant recipient who was converted from a tacrolimus-based regimen to a sirolimus-based regimen four months ago now presents with two weeks of progressive dyspnea, dry cough, and low-grade fever. His oxygen saturation is 92% on room air. Chest CT shows bilateral ground-glass opacities. Infectious workup is negative. Which of the following best describes the most likely cause of his pulmonary findings and the appropriate management?
A) This presentation represents opportunistic pneumonia caused by Pneumocystis jirovecii; sirolimus does not cause pulmonary toxicity, and TMP-SMX prophylaxis should have been continued
B) This is calcineurin inhibitor-induced nephrotoxicity manifesting as pulmonary edema from fluid overload; sirolimus should be continued and diuresis initiated
C) This is a hypersensitivity reaction to sirolimus caused by IgE-mediated mast cell degranulation; antihistamines and dose reduction are the appropriate response
D) This is sirolimus-induced pneumonitis — a class-specific adverse effect of mTOR inhibitors occurring in 3 to 11% of patients; sirolimus should be discontinued and the patient evaluated for drug-induced lung injury
E) This represents acute cellular rejection of the allograft manifesting with pulmonary infiltrates; immunosuppression should be increased with pulse corticosteroids
ANSWER: D
Rationale:
Sirolimus-induced pneumonitis is a class-specific adverse effect of mTOR inhibitors, occurring in approximately 3 to 11% of patients. It ranges from asymptomatic radiographic infiltrates to severe organizing pneumonia or alveolar hemorrhage. The mechanism involves mTOR inhibitor effects on immune cell trafficking and cytokine production in the lung. Clinically, it presents as subacute progressive dyspnea, cough, and hypoxia — often weeks to months after initiation or dose change. Ground-glass opacities on CT are characteristic. Any new respiratory symptoms in a patient on an mTOR inhibitor must prompt chest imaging and, if drug-induced pneumonitis is suspected after infectious workup, discontinuation of the mTOR inhibitor. Resolution typically follows drug cessation.
Option A: Option A is incorrect: while Pneumocystis jirovecii pneumonia (PJP) is an important opportunistic infection in transplant recipients and must be excluded, the scenario states the infectious workup is negative. Furthermore, mTOR inhibitor-induced pneumonitis is a well-established and important class-specific toxicity that must be recognized.
Option B: Option B is incorrect: pulmonary edema from fluid overload would typically present with bilateral perihilar or dependent infiltrates on imaging and signs of volume overload on examination. More critically, CNI nephrotoxicity does not present as pulmonary toxicity — this conflates two unrelated adverse effects.
Option C: Option C is incorrect: mTOR inhibitor pneumonitis is not an IgE-mediated hypersensitivity reaction. It is a drug-induced lung injury thought to involve aberrant immune cell activity in the lung parenchyma — a different mechanism from classic allergic reactions. Antihistamines are not the management.
Option E: Option E is incorrect: acute cellular rejection of the kidney allograft does not present with pulmonary infiltrates. Pulmonary manifestations of rejection do not occur in kidney transplant recipients — the infiltrates in this scenario are in the transplanted organ's distant site (the lung) and are caused by the immunosuppressant drug, not the rejection process.
14. A transplant surgeon is planning to convert a kidney transplant recipient from tacrolimus to sirolimus (an mTOR inhibitor) as part of a calcineurin inhibitor-sparing strategy to preserve renal function. The recipient received his transplant 6 weeks ago and his surgical wound has not yet fully healed. A colleague advises against initiating sirolimus at this time. Which of the following best explains why mTOR inhibitors are typically avoided in the early post-operative period?
A) mTOR inhibitors are potent CYP3A4 inducers and would dramatically reduce cyclosporine and tacrolimus levels, precipitating acute rejection during the transition period
B) mTOR inhibitors cause severe early nephrotoxicity through afferent arteriolar vasoconstriction, which is additive with the surgical ischemia-reperfusion injury and irreversible if initiated within the first 3 months
C) mTOR inhibitors inhibit fibroblast proliferation and reduce collagen deposition, impairing wound healing and increasing the risk of wound dehiscence, lymphocele formation, and incisional hernia
D) mTOR inhibitors cause profound thrombocytopenia within the first 4 weeks of use, increasing the risk of hemorrhage from incompletely healed surgical wounds
E) mTOR inhibitors are absolutely contraindicated in combination with tacrolimus in the early post-transplant period because of additive calcineurin inhibition causing irreversible nephrotoxicity
ANSWER: C
Rationale:
mTOR inhibitors impair wound healing through a well-characterized mechanism: inhibition of mTORC1 suppresses fibroblast proliferation and reduces collagen deposition — two processes essential for normal tissue repair. This clinically important adverse effect increases the risk of wound dehiscence (separation of the surgical incision), lymphocele formation (a fluid collection at the surgical site from disrupted lymphatics), and incisional hernia. For this reason, mTOR inhibitors are typically avoided for the first 4 to 12 weeks after transplant surgery and after any major surgery. Conversion to an mTOR inhibitor-based regimen is deferred until surgical healing is confirmed.
Option A: Option A is incorrect: mTOR inhibitors are substrates of CYP3A4, not inducers of it. They would not accelerate metabolism of co-administered CNIs — quite the opposite, as any CYP3A4-interacting drug would affect mTOR inhibitor levels, not drive CNI levels down.
Option B: Option B is incorrect: mTOR inhibitors do not cause nephrotoxicity through afferent arteriolar vasoconstriction — that is the mechanism of calcineurin inhibitor nephrotoxicity. mTOR inhibitors do not cause nephrotoxicity per se, though they can impair renal recovery when combined with CNIs at standard doses.
Option D: Option D is incorrect: while mTOR inhibitors can cause thrombocytopenia as an adverse effect, this is not the primary reason they are avoided post-operatively. The wound healing impairment is the dominant and most well-characterized surgical contraindication.
Option E: Option E is incorrect: mTOR inhibitors do not inhibit calcineurin — they act on mTORC1, a completely different downstream target. There is no additive calcineurin inhibition when mTOR inhibitors are combined with tacrolimus, and this combination is in fact a standard CNI-sparing strategy once the post-operative wound healing period has passed.
15. Azathioprine is an immunosuppressive prodrug (a drug that is inactive as given and must be converted to an active form in the body) used in transplantation and autoimmune diseases. After oral administration, it is cleaved non-enzymatically to 6-mercaptopurine (6-MP). The 6-MP then undergoes metabolism along several competing pathways. Which of the following correctly identifies the active immunosuppressive metabolites of azathioprine and the enzyme responsible for producing them?
A) 6-MP is converted to thiouric acid by thiopurine methyltransferase (TPMT); thiouric acid is the active immunosuppressive metabolite that incorporates into DNA
B) 6-MP is converted directly to azathioprine by a reversible non-enzymatic reaction; azathioprine itself is the active DNA-damaging species
C) 6-MP is methylated by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) to 6-methylmercaptopurine (6-MMP), which competitively inhibits purine synthesis
D) 6-MP is oxidized by xanthine oxidase (XO) to thioguanine nucleotides (TGNs); TGNs are the active metabolites that incorporate into DNA and cause strand breaks
E) 6-MP is converted to thioguanine nucleotides (TGNs) via hypoxanthine-guanine phosphoribosyltransferase (HGPRT); TGNs are the active immunosuppressive metabolites that incorporate into DNA, causing strand breaks and inhibiting purine synthesis
ANSWER: E
Rationale:
In the anabolic (activating) metabolic pathway, 6-MP is converted to thioguanine nucleotides (TGNs) through the action of hypoxanthine-guanine phosphoribosyltransferase (HGPRT). TGNs are the active immunosuppressive metabolites — they incorporate into cellular DNA as fraudulent bases, causing strand breaks, and also inhibit purine synthesis de novo. Lymphocytes are particularly sensitive to TGN-mediated DNA damage because they rely heavily on de novo purine synthesis for proliferation. Understanding which metabolite is active and which pathway produces it is essential for predicting the consequences of enzyme inhibition (as with allopurinol-XO inhibition) and genetic variation (as with TPMT polymorphisms).
Option A: Option A is incorrect: thiouric acid is the inactive end product of the xanthine oxidase (XO) catabolic pathway — it is excreted in urine and has no immunosuppressive activity. TPMT does not produce thiouric acid; XO does.
Option B: Option B is incorrect: azathioprine is the prodrug, not the active molecule. The conversion of azathioprine to 6-MP by non-enzymatic cleavage is the activation step that begins azathioprine's immunosuppressive activity — not the reversal of it.
Option C: Option C is incorrect: HGPRT converts 6-MP to TGNs (the active metabolites) — not to 6-methylmercaptopurine (6-MMP). 6-MMP is produced by thiopurine methyltransferase (TPMT) as part of the inactivation (methylation) pathway. This option confuses both the enzyme and the product.
Option D: Option D is incorrect: xanthine oxidase (XO) converts 6-MP to thiouric acid as the catabolic (inactivating) pathway — it does not produce TGNs. Inhibiting XO with allopurinol blocks this catabolic route, causing 6-MP to accumulate and shunting more drug toward TGN production, which is why allopurinol coadministration with azathioprine causes dangerous myelosuppression.
16. A kidney transplant recipient on azathioprine for maintenance immunosuppression develops a painful acute gout flare. His primary care physician, unaware of his transplant medications, prescribes allopurinol (a drug used to lower uric acid levels by inhibiting the enzyme xanthine oxidase, or XO). Two weeks later, the patient is admitted with fever, severe pancytopenia (dangerously low counts of all blood cell types), and sepsis. Which of the following best explains the mechanism of this life-threatening drug interaction?
A) Allopurinol competitively inhibits calcineurin, directly enhancing the immunosuppressive effect of azathioprine and causing profound over-immunosuppression
B) Allopurinol inhibits xanthine oxidase (XO), which is the primary catabolic (inactivating) enzyme for 6-mercaptopurine (6-MP); blocking XO prevents 6-MP breakdown and causes 4-fold accumulation of thioguanine nucleotides (TGNs) — the bone marrow-toxic active metabolites of azathioprine
C) Allopurinol inhibits thiopurine methyltransferase (TPMT), redirecting 6-MP from the methylation pathway toward the xanthine oxidase pathway, increasing thiouric acid production and causing direct bone marrow toxicity
D) Allopurinol and azathioprine compete for active tubular secretion in the kidney, causing azathioprine to accumulate in the bloodstream to toxic concentrations
E) Allopurinol alkalinizes the urine, reducing renal clearance of azathioprine and its metabolites, causing progressive drug accumulation over several weeks
ANSWER: B
Rationale:
Allopurinol inhibits xanthine oxidase (XO), which is one of the three major metabolic pathways for 6-MP — specifically the catabolic (inactivating) pathway that converts 6-MP to the inactive metabolite thiouric acid for urinary excretion. When XO is blocked by allopurinol, 6-MP cannot be degraded efficiently and accumulates, shunting increased drug flux through the anabolic HGPRT pathway toward thioguanine nucleotide (TGN) production. The result is a roughly 4-fold increase in TGN concentrations in bone marrow precursor cells, causing severe, potentially fatal pancytopenia. Coadministration of allopurinol with azathioprine at standard doses is therefore absolutely contraindicated unless the azathioprine dose is reduced by 67 to 75% — and even then requires intensive hematological monitoring.
Option A: Option A is incorrect: allopurinol has no interaction with calcineurin and no direct immunosuppressive mechanism. Its sole relevant action in this context is inhibition of xanthine oxidase and the resulting metabolic consequences for 6-MP.
Option C: Option C is incorrect: allopurinol does not inhibit TPMT. TPMT is a separate enzyme (thiopurine methyltransferase) that inactivates 6-MP via methylation. The important clinical consideration with TPMT is genetic polymorphisms — not allopurinol inhibition.
Option D: Option D is incorrect: azathioprine and its metabolites are not primarily renally cleared via active tubular secretion. The interaction is metabolic (enzymatic), not pharmacokinetic competition at the kidney.
Option E: Option E is incorrect: urinary alkalinization does not meaningfully affect azathioprine or TGN clearance. Azathioprine's disposition is dominated by enzymatic metabolism, not urinary excretion, and is not pH-sensitive in the clinically relevant range.
17. Before initiating azathioprine for a patient with a newly diagnosed autoimmune condition, a physician orders TPMT (thiopurine methyltransferase — an enzyme that inactivates 6-mercaptopurine by adding a methyl group) genotyping. The result shows the patient is homozygous for low-activity alleles (meaning both copies of the TPMT gene carry variants that produce a non-functional enzyme). This genotype is present in approximately 0.3% of the population. Which of the following best describes the clinical implication of this finding for azathioprine dosing?
A) This patient has severely reduced or absent TPMT activity; without the TPMT inactivation pathway, nearly all 6-MP is shunted toward thioguanine nucleotide (TGN) production, causing severe and potentially fatal myelosuppression at standard azathioprine doses; azathioprine should be used at substantially reduced doses or avoided entirely
B) This patient has high TPMT activity due to gene amplification; excess methylation of 6-MP produces elevated 6-methylmercaptopurine (6-MMP), which directly causes hepatotoxicity; azathioprine dose should be increased to overcome the increased metabolic clearance
C) This patient is a heterozygous carrier of one low-activity allele and requires a 30 to 50% dose reduction from standard dosing to achieve therapeutic TGN levels without excess toxicity
D) This patient has normal TPMT activity and can receive standard azathioprine dosing; TPMT genotyping only affects thiopurine dosing when xanthine oxidase (XO) inhibitors are co-prescribed
E) The TPMT result is irrelevant for azathioprine because azathioprine's dose is controlled entirely by monitoring complete blood count (CBC) results in the first four weeks of therapy regardless of genotype
ANSWER: A
Rationale:
Individuals who are homozygous for low-activity TPMT alleles (TPMT-deficient, approximately 0.3% of the population) have severely reduced or absent TPMT enzyme activity. Since TPMT provides one of the three metabolic routes for 6-MP breakdown, these patients cannot inactivate 6-MP via methylation. The result is that nearly all 6-MP is channeled into the HGPRT anabolic pathway, producing markedly elevated thioguanine nucleotide (TGN) concentrations in hematopoietic cells. At standard azathioprine doses, this produces severe, potentially fatal pancytopenia. CPIC (Clinical Pharmacogenomics Implementation Consortium) guidelines recommend substantial dose reduction or avoidance of azathioprine in TPMT-deficient patients, with an alternative antimetabolite considered. TPMT genotyping before initiating azathioprine is now standard of care.
Option B: Option B is incorrect: this option describes the opposite scenario — a patient with high rather than low TPMT activity. Homozygous low-activity alleles produce reduced enzyme function, not amplified activity. High TPMT activity is associated with reduced TGN production and potentially subtherapeutic immunosuppression, not hepatotoxicity.
Option C: Option C is incorrect: a 30 to 50% dose reduction is the recommendation for heterozygous carriers (one low-activity allele, resulting in intermediate TPMT activity) — not for homozygous TPMT-deficient patients. The homozygous-deficient patient requires much more dramatic dose modification or an alternative drug.
Option D: Option D is incorrect: TPMT genotyping is clinically actionable independent of XO inhibitor co-administration. TPMT-deficient patients are at risk for severe myelosuppression from azathioprine alone, without any XO inhibitor interaction.
Option E: Option E is incorrect: while CBC monitoring is essential during azathioprine therapy, knowing the TPMT genotype before initiation allows the prescriber to anticipate and prevent myelosuppression rather than detect it after it has already occurred — the pharmacogenomic testing is prospective risk stratification, not a substitute for monitoring.
18. Mycophenolate mofetil (MMF) is a prodrug that is rapidly converted in the body to mycophenolic acid (MPA), the active compound. MPA inhibits inosine monophosphate dehydrogenase (IMPDH — the rate-limiting enzyme in the de novo purine synthesis pathway, meaning the pathway by which cells build purine nucleotides from scratch rather than recycling existing ones). What property of lymphocytes makes them uniquely sensitive to IMPDH inhibition compared to most other cell types in the body?
A) Lymphocytes express a drug-sensitizing isoform of IMPDH (IMPDH3) found only in immune cells, which has higher affinity for MPA than the isoforms found in other tissues
B) Lymphocytes have unusually high baseline IMPDH enzyme activity, making them the first cells to be affected when IMPDH is partially inhibited by MPA
C) Lymphocytes lack mitochondrial DNA and therefore require cytoplasmic de novo purine synthesis exclusively, while other cells use mitochondrial purine recycling pathways
D) Unlike most other cell types in the body, lymphocytes rely almost exclusively on the de novo purine synthesis pathway for DNA synthesis because they lack functional purine salvage pathway enzymes; IMPDH inhibition therefore selectively starves lymphocytes of the purine precursors required for DNA replication and proliferation
E) Lymphocytes express IMPDH on their cell surface rather than intracellularly, allowing MPA to inhibit the enzyme before it enters the cell and making lymphocytes more accessible to drug action than cells where IMPDH is intracellular
ANSWER: D
Rationale:
The selectivity of mycophenolic acid (MPA) for lymphocytes is based on a fundamental difference in purine metabolism. Most cell types in the body can synthesize purines through either the de novo synthesis pathway or the salvage pathway (which recycles preformed purine bases from DNA breakdown). Lymphocytes, however, are uniquely dependent on the de novo synthesis pathway because they lack fully functional purine salvage pathway enzymes. When IMPDH — the rate-limiting step in de novo synthesis — is inhibited by MPA, lymphocytes cannot meet the massive demand for purines required for rapid DNA replication during an immune response. Other cell types with intact salvage pathways are relatively spared because they can continue synthesizing purines via the alternative route. This mechanistic selectivity is what makes MMF an effective lymphocyte-specific immunosuppressant rather than a broadly cytotoxic agent.
Option A: Option A is incorrect: while lymphocytes do express IMPDH2 (the type 2 isoform, which is more highly expressed in proliferating cells including lymphocytes) rather than IMPDH3, the primary basis for selective lymphocyte sensitivity is the lack of a functional salvage pathway — not simply isoform-based affinity differences.
Option B: Option B is incorrect: the explanation for MMF selectivity is not related to absolute baseline IMPDH activity levels in lymphocytes relative to other cells. The key is the alternative salvage pathway that other cell types can use when IMPDH is inhibited.
Option C: Option C is incorrect: this option attributes lymphocyte sensitivity to a feature of mitochondrial DNA biology that is not the established mechanism. The lack of a functional purine salvage pathway in lymphocytes — not mitochondrial biology — is the reason for their unique dependence on IMPDH.
Option E: Option E is incorrect: IMPDH is an intracellular enzyme in all cell types, including lymphocytes. MPA enters cells and inhibits IMPDH intracellularly — it does not act at the cell surface.
19. A 28-year-old woman with a kidney transplant performed two years ago is currently maintained on tacrolimus, mycophenolate mofetil (MMF), and low-dose prednisone. She informs her transplant physician that she and her partner are planning to attempt conception in the next several months. Which of the following statements about MMF and pregnancy is correct and should guide the counseling discussion?
A) MMF is safe in the first trimester only and should be discontinued at 13 weeks gestation when organogenesis is complete
B) MMF carries a small but acceptable risk of fetal harm similar to that of low-dose corticosteroids; continuation with close fetal surveillance is appropriate if immunosuppression cannot be reduced
C) MMF is a potent human teratogen (a drug that causes birth defects) that is absolutely contraindicated in pregnancy; it causes structural fetal malformations in up to 25% of exposed pregnancies and should be switched to azathioprine before conception is attempted
D) MMF is the preferred antimetabolite during pregnancy in transplant recipients because it provides superior protection against acute rejection compared to azathioprine, which must be discontinued once pregnancy is confirmed
E) MMF-induced fetal risk applies only to the first 8 weeks of pregnancy; women who become pregnant unexpectedly can safely continue MMF beyond the first trimester without meaningful additional risk
ANSWER: C
Rationale:
Mycophenolate mofetil (MMF) is classified as a known human teratogen under the FDA Pregnancy and Lactation Labeling Rule (PLLR). It causes serious structural fetal malformations — including cleft palate, microtia (abnormal ear development), limb hypoplasia, and cardiac defects — in up to 25% of exposed pregnancies. MMF is absolutely contraindicated throughout pregnancy and requires reliable contraception in all women of childbearing potential during therapy. The FDA requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program for new MMF prescriptions in women of childbearing age. For transplant recipients planning pregnancy, MMF should be switched to azathioprine — which, while not entirely free of pregnancy risk, is considered a safer alternative antimetabolite with a much more established track record in pregnant transplant recipients. This switch should be made at least 6 weeks before attempting conception.
Option A: Option A is incorrect: MMF is not safe in any trimester. Organogenesis does occur primarily in the first trimester, but MMF's teratogenic risk is not limited to this window — it is an absolute contraindication throughout pregnancy, not just after 13 weeks.
Option B: Option B is incorrect: MMF's fetal risk is not comparable to that of low-dose corticosteroids. Corticosteroids carry real risks (including cleft palate at high doses) but are used in pregnancy when the benefit outweighs risk. MMF causes catastrophic structural malformations in a substantial proportion of exposed pregnancies — an entirely different risk category.
Option D: Option D is incorrect: azathioprine is precisely the preferred antimetabolite during pregnancy, not MMF. The option reverses the correct recommendation.
Option E: Option E is incorrect: there is no "safe window" after the first trimester for MMF exposure in pregnancy. The drug is contraindicated throughout pregnancy, and unexpected pregnancies in MMF-treated patients require urgent counseling and drug transition.
20. Corticosteroids such as prednisone and methylprednisolone suppress inflammation and immune activation through genomic mechanisms — meaning they work by entering cells, binding an intracellular receptor, and directly altering gene expression. One of the most important genomic mechanisms is called transrepression (the ability of the activated glucocorticoid receptor to block the activity of pro-inflammatory transcription factors — proteins that switch on genes encoding inflammatory mediators). Which of the following correctly identifies the transcription factors blocked by the transrepression mechanism and the clinical consequence of this blockade?
A) The activated glucocorticoid receptor blocks the transcription factor NFAT, preventing IL-2 production — the same mechanism used by calcineurin inhibitors but achieved through a different pathway
B) The activated glucocorticoid receptor blocks the transcription factor STAT3 (signal transducer and activator of transcription 3), preventing IL-6 signaling and reducing acute-phase protein production in the liver
C) The activated glucocorticoid receptor blocks the transcription factor mTORC1, preventing lymphocyte cell cycle progression from G1 to S phase — the same mechanism used by mTOR inhibitors at a different binding site
D) The activated glucocorticoid receptor blocks ribosomal protein S6 kinase 1 (S6K1), preventing protein synthesis in activated macrophages and reducing cytokine secretion
E) The activated glucocorticoid receptor directly binds and blocks the transcription factors NF-κB (nuclear factor kappa B) and AP-1 (activator protein 1) without DNA binding, suppressing transcription of genes encoding TNF-α, IL-1β, IL-6, COX-2, and other pro-inflammatory mediators — this mechanism, called transrepression, accounts for much of the clinical anti-inflammatory effect of corticosteroids
ANSWER: E
Rationale:
In the transrepression mechanism of glucocorticoid action, the activated glucocorticoid receptor (GR) — after binding corticosteroid and translocating to the nucleus — physically interacts with and blocks the transcriptional activity of NF-κB (nuclear factor kappa B) and AP-1 (activator protein 1) without itself binding to DNA. NF-κB and AP-1 are master pro-inflammatory transcription factors that drive transcription of multiple key inflammatory genes, including TNF-α (tumor necrosis factor-alpha), IL-1β (interleukin-1 beta), IL-6, IL-8, COX-2 (cyclooxygenase-2), and ICAM-1. By blocking these transcription factors, corticosteroids suppress the entire downstream inflammatory mediator profile simultaneously — accounting for much of the broad anti-inflammatory and immunosuppressive clinical effect seen with these drugs.
Option A: Option A is incorrect: NFAT is the downstream target of calcineurin inhibitors and is blocked by the drug-immunophilin-calcineurin mechanism. Corticosteroids do not work through NFAT; their primary genomic immunosuppressive mechanism targets NF-κB and AP-1. While corticosteroids may reduce IL-2 production as a downstream consequence, the molecular mechanism is distinct.
Option B: Option B is incorrect: STAT3 is involved in IL-6 signaling and is targeted by some biologic agents (such as tocilizumab), but STAT3 is not the primary transcription factor blocked by glucocorticoid transrepression. NF-κB and AP-1 are the established targets of corticosteroid transrepression.
Option C: Option C is incorrect: mTORC1 is a kinase complex targeted by mTOR inhibitors — not a transcription factor blocked by the glucocorticoid receptor. Corticosteroids have no direct interaction with mTORC1.
Option D: Option D is incorrect: S6K1 is a downstream effector of mTORC1 involved in protein synthesis — it is not a target of corticosteroid action. Confusing mTOR pathway components with glucocorticoid receptor targets would represent a fundamental mechanistic misunderstanding.
21. A 45-year-old patient with end-stage renal disease is about to undergo a first kidney transplant from a deceased donor. He is considered standard immunological risk (no pre-formed antibodies against the donor, no prior transplants, no high-risk sensitization events). The transplant team plans induction immunosuppression (an intensive immunosuppressive strategy given at the time of transplant to prevent early acute rejection). Basiliximab is selected for induction. Which of the following correctly describes basiliximab's mechanism and dosing?
A) Basiliximab is a chimeric anti-CD25 monoclonal antibody that blocks IL-2-mediated T-cell proliferation by competitively antagonizing IL-2 binding to the alpha chain of the high-affinity IL-2 receptor; it is given as two fixed doses of 20 mg intravenously on day 0 and day 4 post-transplant and saturates the IL-2 receptor for approximately 4 to 6 weeks
B) Basiliximab is a polyclonal rabbit antibody directed against multiple T-cell surface antigens (including CD3, CD4, CD8, CD25, and CD28) that depletes T cells through complement-dependent cytotoxicity; it is given daily for 3 to 7 days and is associated with cytokine release syndrome requiring pre-medication
C) Basiliximab is a monoclonal anti-CD20 antibody that depletes B cells by targeting the CD20 antigen on their surface; it prevents antibody-mediated rejection in standard-risk recipients by eliminating DSA-producing B cells before transplant
D) Basiliximab is an anti-thymocyte globulin preparation derived from immunized horses that provides broad T-cell depletion and is preferred for high immunological risk recipients over monoclonal antibody induction
E) Basiliximab is a fusion protein that blocks the CD28 co-stimulatory pathway in T cells, preventing T-cell activation by blocking the interaction between CD28 on T cells and B7 ligands on antigen-presenting cells
ANSWER: A
Rationale:
Basiliximab is a chimeric (part human, part mouse) monoclonal antibody directed against the CD25 antigen — the alpha chain (also called the IL-2 receptor alpha chain, or IL-2Rα) of the high-affinity IL-2 receptor on activated T cells. By blocking CD25, basiliximab competitively prevents IL-2 from binding to its high-affinity receptor, blocking the proliferative signal that IL-2 delivers to activated T cells. The dosing is two fixed doses: 20 mg IV on day 0 (at the time of transplant) and 20 mg IV on day 4 post-transplant. This two-dose regimen saturates CD25 receptors for approximately 4 to 6 weeks — the highest-risk period for early acute rejection. Basiliximab is well tolerated with minimal adverse effects and is standard induction in standard-risk kidney transplant recipients.
Option B: Option B is incorrect: the description of a polyclonal preparation targeting multiple T-cell antigens causing complement-dependent cytotoxicity and requiring cytokine release syndrome pre-medication describes anti-thymocyte globulin (ATG) — not basiliximab. Basiliximab is a highly specific monoclonal antibody, not a polyclonal preparation, and does not cause lymphocyte depletion or cytokine release syndrome.
Option C: Option C is incorrect: anti-CD20 monoclonal antibody targeting B cells describes rituximab, not basiliximab. Basiliximab targets CD25 on T cells, not CD20 on B cells.
Option D: Option D is incorrect: the description of an anti-thymocyte globulin derived from immunized horses describes equine ATGAM — basiliximab is a chimeric monoclonal antibody. Additionally, ATG-based preparations (equine or rabbit) are preferred for high-risk recipients; basiliximab is the standard for standard-risk recipients.
Option E: Option E is incorrect: blocking the CD28 co-stimulatory pathway with a B7-binding fusion protein describes belatacept (Nulojix), which blocks the interaction between CD28 on T cells and CD80/CD86 (B7 ligands) on antigen-presenting cells. This is an entirely different mechanism and drug class from basiliximab.
22. A kidney transplant recipient who received standard-risk induction with basiliximab is now 10 days post-transplant. His serum creatinine begins rising on day 7 and an allograft biopsy confirms Banff Grade I acute cellular rejection (ACR — a type of rejection driven by recipient T cells attacking the transplanted organ). He receives a 3-day course of intravenous pulse methylprednisolone (1,000 mg daily), but his creatinine continues to rise. The team diagnoses steroid-resistant ACR and switches to rabbit anti-thymocyte globulin (rATG, thymoglobulin). Which of the following best describes the mechanism by which rATG exerts its immunosuppressive effect?
A) rATG is a humanized anti-CD25 monoclonal antibody that blocks IL-2 receptor signaling on T cells — the same target as basiliximab, but with greater binding affinity, allowing it to overcome basiliximab-resistant rejection
B) rATG inhibits calcineurin in residual T cells that have escaped basiliximab's IL-2 receptor blockade, providing a pharmacological mechanism complementary to tacrolimus in the maintenance regimen
C) rATG is a polyclonal antibody preparation (derived from rabbits immunized with human thymocytes) that binds multiple T-cell surface antigens including CD3, CD4, CD8, CD25, CD28, and CD45, depleting T lymphocytes through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC)
D) rATG inhibits mTORC1 in activated T cells through a mechanism that bypasses the FKBP-12 binding step, producing T-cell cycle arrest without requiring the immunophilin-dependent mechanism used by sirolimus
E) rATG is a bispecific antibody that simultaneously binds CD3 on T cells and the donor HLA antigen on transplanted cells, redirecting T cells away from the allograft and toward activated phagocytes for elimination
ANSWER: C
Rationale:
Rabbit anti-thymocyte globulin (rATG, thymoglobulin) is a polyclonal antibody preparation made by immunizing rabbits with human thymocytes (immature T cells from the thymus) and then collecting the resulting rabbit immunoglobulins. The preparation contains antibodies directed against a broad array of T-cell surface antigens including CD3 (T-cell receptor signaling complex), CD4 (helper T-cell co-receptor), CD8 (cytotoxic T-cell co-receptor), CD25 (IL-2 receptor alpha chain), CD28 (co-stimulatory receptor), CD45 (common leukocyte antigen), and others. These antibodies deplete T lymphocytes through two mechanisms: complement-dependent cytotoxicity (CDC), in which complement proteins activated by antibody binding lyse the T cell, and antibody-dependent cellular cytotoxicity (ADCC), in which Fc receptor-bearing natural killer cells and macrophages kill antibody-coated T cells. The result is profound and prolonged lymphocyte depletion. rATG is used both for high immunological risk induction and for treatment of steroid-resistant ACR.
Option A: Option A is incorrect: rATG is not a monoclonal anti-CD25 antibody — that describes basiliximab or daclizumab. rATG is a polyclonal preparation with a much broader target spectrum and depletes T cells outright, rather than merely blocking a single receptor.
Option B: Option B is incorrect: rATG does not inhibit calcineurin. It is a polyclonal antibody acting at the T-cell surface to cause lymphocyte depletion through immune effector mechanisms — it has no intracellular calcineurin-inhibiting activity.
Option D: Option D is incorrect: rATG does not inhibit mTORC1 by any mechanism. mTOR inhibition by sirolimus requires FKBP-12 binding followed by mTORC1 inhibition — rATG is an antibody with no mTOR-related pharmacology.
Option E: Option E is incorrect: bispecific T-cell engager (BiTE) antibodies that redirect T cells toward target cells are a cancer immunotherapy approach (e.g., blinatumomab) — they are not the mechanism of rATG. rATG depletes T cells; it does not redirect them.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.